Press Releases

Press Releases

Date Title
07/09/19 Vaxart Enters into Research Collaboration with Janssen to Evaluate Oral Universal Influenza Vaccine
Oral Universal Flu Vaccine Candidate to be Evaluated in Pre-Clinical Challenge Model SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 9, 2019-- Vaxart, Inc. , ( Vaxart ), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by
06/20/19 Vaxart to Present at ASM Microbe 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 20, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced that Roberto Mateo , Ph.D., senior scientist at Vaxart ,
05/29/19 New Publication in Vaccine Highlights Preclinical Results of Vaxart’s Mucosal Chikungunya Vaccine
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 29, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the publication of the comprehensive results from a
05/09/19 Vaxart Announces First Quarter 2019 Financial Results and Provides Corporate Update
- $13 million raised in 1H19 - - Norovirus bivalent vaccine Phase 1b clinical study underway with results expected in 2H19 - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 9, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered
04/16/19 Vaxart Doses First Patient in Randomized Cohort of Bivalent Norovirus Vaccine Phase 1b Clinical Trial
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 16, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced it has started dosing subjects in the randomized cohort of the Phase 1b
04/12/19 Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
100% Survival Against Lethal H5N1 Avian Flu Challenge in Ferret Study SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 12, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection,
04/09/19 Vaxart Announces Pricing of Underwritten Public Offering
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 9, 2019-- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced the pricing of an underwritten public
03/28/19 Vaxart to Present at Global Medical Meetings in April
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 28, 2019-- Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced participation in two upcoming global medical meetings in
03/27/19 Vaxart Completes Dosing of the Lead-In Cohort in Bivalent Norovirus Vaccine Phase 1b Clinical Trial
First Oral Norovirus GII.4 Tablet Vaccine Used in Clinical Trial SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 27, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the
03/20/19 Vaxart Announces Closing of Registered Direct Offering of Common Stock
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Mar. 20, 2019-- Vaxart, Inc. , a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of